SJÖGREN’S & LONGEVITY: ENHANCING LIFESPAN AND HEALTHSPAN THROUGH PRECISION IMMUNOLOGY

The FDA has granted Breakthrough Therapy designation to ianalumab for Sjögren’s disease. This is more than just a win for autoimmune patients; it’s a shift in how we approach immune-driven aging. The Science: Dual-Action Control Ianalumab is a first-in-class monoclonal antibody that moves us away from the "blunt instrument" of broad steroids and toward a precise, two-pronged mechanism: 1. Direct Depletion: B cells are a type of white blood cell which act primarily by producing customized antibodies to neutralize pathogens like bacteria and viruses. Ianalumab targets the B-cell Activating Factor Receptor (BAFF-R) to eliminate pathogenic B-cells. 2. Signaling Inhibition: It blocks the underlying pathways to prevent B-cell hyperactivity before it starts. The Longevity Angle: Silencing "Inflammaging" chronic B-cell hyperactivity is a primary driver of systemic "inflammaging." This persistent low-grade inflammation accelerates vascular and neurological decline. By moving to targeted biologics, we achieve two critical goals for healthspan: • Preserving Immune Competence: We "tune" the immune system rather than shutting it down, maintaining our defense against infections. • Organ Preservation: Reducing the total inflammatory burden is essential for maintaining systemic homeostasis. We are officially entering the era of Immune Tuning.